click below
click below
Normal Size Small Size show me how
Chapter 18
Diabetes drugs - endocrine
| Term | Definition |
|---|---|
| Type 1 diabetes | Results from an autoimmune destruction of the pancreatic B cells. Usually develops in persons younger than 30 years old. |
| Type 2 diabetes | Development is attributed to a much more sedentary lifestyle and lack of exercise. Usually develops in persons older than 40 years, however more and more cases are being reported for those under 20 years old. |
| Hyperglycemia | Refers to an abnormally high level of glucose (sugar) in the blood |
| Hypoglycemia | Condition characterized by abnormally low levels of glucose (sugar) in the blood |
| Glycosuria | The presence of glucose (sugar) in the urine |
| Prophylactic | Refers to measures or treatments designed to prevent disease or a condition before it occurs |
| UTI | Urinary tract infection |
| Xerostomia | Medical term for dry mouth |
| Macroangiopathy | Refers to damage or disease affecting the large blood vessels |
| Microangiopathy | Refers to damage or disease affecting the small blood vessels |
| Insulins | insulin aspart (NovoLog), insulin lispro (Humalog), insulin regular (Humulin R), insulin determir (Levemir), insulin glargine (Lantus) |
| Biguanides | metformin (Glucophage) |
| SGLT-2 Inhibitors | canagliflozin (Invokana) |
| GLP-1 Receptors Agonists | liraglutide (Victoza), semaglutide (Ozempic) |
| Sulfonylureas | glimepiride (Amaryl), glipizide (Glucotrol), glyburide (DiaBeta) |
| DPP-4 inhibitors | sitagliptin (Januvia) |
| Thiazolidinediones | pioglitazone (Actos) |
| Meglitinides | repaglinide (Prandin) |
| insulin aspart (NovoLog) class | Rapid acting insulin |
| insulin aspart (NovoLog) indication | Type 1 and type 2 diabetes |
| insulin lispro (Humalog) class | Rapid acting insulin |
| insulin lispro (Humalog) indication | Type 1 and type 2 diabetes |
| insulin regular (Humulin R) class | Short acting insulin |
| insulin regular (Humulin R) indication | Type 1 and type 2 diabetes |
| insulin determir (Levemir) class | Long-acting insulin |
| insulin determir (Levemir) indication | Type 1 and type 2 diabetes |
| insulin glargine (Lantus) class | Long acting insulin |
| insulin glargine (Lantus) indication | Type 1 and type 2 diabetes |
| metformin (Glucophage) class | Biguanides |
| metformin (Glucophage) indication | Type 2 diabetes |
| canagliflozin (Invokana) class | SGLT-2 inhibitors |
| canagliflozin (Invokana) indication | Type 2 diabetes |
| liraglutide (Victoza) class | GLP-1 receptor agonists |
| liraglutide (Victoza) indication | Type 2 diabetes |
| semaglutide (Ozempic) class | GLP-1 receptor agonists |
| semaglutide (Ozempic) indication | Type 2 diabetes |
| glimepiride (Amaryl) class | Sulfonylureas |
| glimepiride (Amaryl) indication | Type 2 diabetes |
| glipizide (Glucotrol) class | Sulfonylureas |
| glipizide (Glucotrol) indication | Type 2 diabetes |
| glyburide (DiaBeta) class | Sulfonylureas |
| glyburide (DiaBeta) indication | Type 2 diabetes |
| sitagliptin (Januvia) class | DPP-4 inhibitors |
| sitagliptin (Januvia) indication | Type 2 diabetes |
| pioglitazone (Actos) class | Thiazolidinediones |
| pioglitazone (Actos) indication | Type 2 diabetes |
| repaglinide (Prandin) class | Meglitinides |
| repaglinide (Prandin) indication | Type 2 diabetes |